Verastem to Present at Upcoming Conferences
March 14 2018 - 7:00AM
Business Wire
Verastem, Inc. (NASDAQ:VSTM), focused on developing and
commercializing drugs to improve the survival and quality of life
of cancer patients, today announced that the Company will present
at the following investor conferences:
- The 28th Annual Oppenheimer & Co.
Healthcare Conference on Tuesday, March 20, 2018 at 11:30am in New
York City, NY, USA.
- The 17th Annual Needham Healthcare
Conference on Tuesday, March 27, 2018 at 5:00pm in New York City,
NY, USA.
A live webcast of each presentation will be available on the
investors section of the Company’s website at www.verastem.com. An
archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company
focused on developing and commercializing drugs to improve the
survival and quality of life of cancer patients. Verastem is
currently developing duvelisib, a dual inhibitor of PI3K-delta and
PI3K-gamma, which has successfully met its primary endpoint in a
Phase 2 study in indolent Non-Hodgkin Lymphoma (iNHL) and a Phase 3
clinical trial in patients with chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL). Verastem has submitted a New
Drug Application (NDA) requesting the full approval of duvelisib
for the treatment of patients with relapsed or refractory CLL/SLL,
and accelerated approval for the treatment of patients with
relapsed or refractory follicular lymphoma (FL). In addition,
Verastem is developing the FAK inhibitor defactinib, which is
currently being evaluated in three separate clinical collaborations
in combination with immunotherapeutic agents for the treatment of
several different cancer types, including pancreatic cancer,
ovarian cancer, non-small-cell lung cancer (NSCLC), and
mesothelioma. Verastem’s product candidates seek to treat cancer by
modulating the local tumor microenvironment and enhancing
anti-tumor immunity. For more information, please visit
www.verastem.com.
Verastem, Inc. forward-looking statements notice
This press release includes forward-looking statements about
Verastem's strategy, future plans and prospects, including
statements regarding the development and activity of Verastem's
investigational product candidates, including duvelisib and
defactinib, and Verastem's PI3K and FAK programs generally, the
structure of our planned and pending clinical trials, Verastem’s
financial guidance and the timeline and indications for clinical
development and regulatory submissions. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan,"
"predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statement. Applicable risks and
uncertainties include the risks that acceptance or approval of the
NDA will not occur on the expected timeframes or at all; that even
if data from clinical trials is positive, regulatory authorities
may require additional studies for approval and the product may not
prove to be safe and effective; that the preclinical testing of
Verastem's product candidates and preliminary or interim data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials; that the full data from the DUO
study will not be consistent with the previously presented results
of the study; that data may not be available when expected,
including for the Phase 3 DUO™ study; that the degree of market
acceptance of product candidates, if approved, may be lower than
expected; that the timing, scope and rate of reimbursement for our
product candidates is uncertain; that there may be competitive
developments affecting our product candidates; that data may not be
available when expected; that enrollment of clinical trials may
take longer than expected; that our product candidates will cause
unexpected safety events or result in an unmanageable safety
profile as compared to their level of efficacy; that duvelisib will
be ineffective at treating patients with lymphoid malignancies;
that Verastem will be unable to successfully initiate or complete
the clinical development of its product candidates; that the
development of Verastem's product candidates will take longer or
cost more than planned; that Verastem may not have sufficient cash
to fund its contemplated operations; that Verastem or Infinity
Pharmaceuticals, Inc. (Infinity) will fail to fully perform under
the duvelisib license agreement; that Verastem may be unable to
make additional draws under its debt facility or obtain adequate
financing in the future through product licensing, co-promotional
arrangements, public or private equity, debt financing or
otherwise; that Verastem will not pursue or submit regulatory
filings for its product candidates, including for duvelisib in
patients with CLL/SLL or iNHL; and that Verastem's product
candidates will not receive regulatory approval, become
commercially successful products, or result in new treatment
options being offered to patients. Other risks and uncertainties
include those identified under the heading "Risk Factors" in
Verastem's Annual Report on Form 10-K for the year ended December
31, 2017 and in any subsequent filings with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Verastem's views as of the date of this
release, and Verastem does not undertake and specifically disclaims
any obligation to update any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180314005131/en/
Verastem, Inc.Marianne M. Lambertson, 781-292-4273Vice
President, Corporate CommunicationsInvestor Relations/Public
Relationsmlambertson@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Sep 2023 to Sep 2024